Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 25, 2026

Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

View original at finance.yahoo.com
Arteris Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 Arteris, Inc. Arteris joins the ranks of Google, Nvidia, Adidas, Walmart, and more in Fast Company’s annual World’s Most Innovative Companies of 2026 list…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve, from automating complex network-on-chip creation to enabling secure, scalable data movement for billions of chips

    60% confidence
  • FlexGen enables teams to generate optimized interconnects in a fraction of the time with significantly improved power, performance, and area results

    60% confidence
  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve, from automating complex network-on-chip creation to enabling secure, scalable data movement for billions of chips

    60% confidence
  • Arteris is committed to addressing rapid changes in the semiconductor industry and setting new standards for innovation

    60% confidence
  • FlexGen is the industry's first smart network-on-chip (NoC) IP

    60% confidence
  • Arteris is honored to receive Fast Company recognition as it reflects their commitment to addressing rapid changes in the semiconductor industry and setting new standards for innovation

    60% confidence
  • Arteris is committed to addressing rapid changes in the semiconductor industry and setting new standards for what is possible through innovation

    60% confidence
  • FlexGen is the industry's first smart network-on-chip IP

    60% confidence
  • Arteris is committed to addressing rapid changes in the semiconductor industry and setting new standards for what is possible through innovation

    60% confidence
  • FlexGen enables teams to generate optimized interconnects in a fraction of the time with significantly improved power, performance, and area (PPA) results

    60% confidence
  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve

    60% confidence
  • FlexGen enables teams to generate optimized interconnects in a fraction of the time with significantly improved power, performance, and area results

    60% confidence
  • Arteris network-on-chip technology has been shipped in more than 4 billion chips and chiplets for major customers and numerous emerging AI innovators globally

    60% confidence
  • Arteris is focused on solving the industry's toughest challenges as AI and chiplet-based architectures continue to evolve, from automating complex network-on-chip creation to enabling secure, scalable data movement

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com